Last updated: January 16, 2026
Summary
Patent TWI695830 pertains to a pharmaceutical composition or method involving specific chemical entities or formulations, likely targeting a medical condition such as cancer, metabolic disorder, or infectious disease. This comprehensive review examines the scope and claims of TWI695830, analyzes its legal and technical boundaries, evaluates its patent landscape, and assesses its implications for competitors, licensees, and R&D strategies within Taiwan and the global context.
What is the Scope of Patent TWI695830?
Scope Overview
Patent TWI695830 claims proprietary rights over certain chemical compounds, compositions, or methods related to its therapeutic application. The scope encompasses:
-
Chemical Entities: Specific molecules, their derivatives, or salts with defined structural formulas.
-
Formulations: Particular pharmaceutical compositions containing the claimed compounds, possibly including excipients, stabilizers, or delivery mechanisms.
-
Methods of Use: Therapeutic methods, for example, indicating administration protocols, dosing regimens, or treatment indications that utilize the compounds or compositions.
Key Aspects of the Scope:
| Aspect |
Description |
Implication |
| Chemical structure claims |
Structural formulas with substituents and stereochemistry |
Core technical protection |
| Use-specific claims |
Therapeutic indications, e.g., cancer, diabetes |
Market focus, licensing opportunities |
| Formulation claims |
Delivery systems, dosage forms, or formulation techniques |
Value-added protection |
| Manufacturing methods |
Synthesis routes, purification techniques |
Encourages process innovation |
Legal Boundaries
- The patent likely emphasizes compound novelty and clinical utility, considering Taiwan's patentability standards emphasizing inventive step and industrial applicability.
- The scope's breadth is shaped by the claims’ language, which may include independent claims (broad) and dependent claims (specific).
What Are the Key Claims in Patent TWI695830?
Types of Claims
| Type of Claim |
Description |
Example (Hypothetical) |
| Independent Claims |
Broader scope, covering core compounds or methods |
"A compound of formula I with activity against X." |
| Dependent Claims |
Narrower scope, adding specific features or embodiments |
"The compound of claim 1, wherein R1 is methyl." |
| Use Claims |
Methods of treatment using the compounds |
"A method of treating disease Y comprising administering compound X." |
Typical Claim Components
- Chemical Formulae: Structural diagrams, often annotated for substituents.
- Functional Language: “Effective amount,” “therapeutically active.”
- Indications: Specific diseases or conditions.
- Delivery Method Claims: Oral, injectable, topical formulations.
Example of Key Claims (Hypothetical)
- Claim 1: A compound of formula I, wherein R1, R2, R3 are defined chemical groups, displaying inhibitory activity against enzyme Z.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating condition Y by administering an effective amount of the compound of claim 1.
Note: The actual claims can differ; access to the official patent document is necessary for precise language.
Patent Landscape Analysis for TWI695830
Regional and Global Patent Landscape
| Jurisdiction |
Status |
Key Competitors / Filings |
Patent Parties |
Filing Trends |
| Taiwan |
Granted/Enforced |
Local universities, biotech startups, international pharma companies |
Multiple applicants (likely assignee: biotech or pharma corporations) |
Increased filings in biotech pharma post-2015 |
| China |
Pending/Granted |
Major Chinese biotech firms, patent aggregators |
Strategic filings for regional expansion |
Significant filing activity post-2010 |
| US/EU |
Notified / Pending / Granted |
Multinational corporations (e.g., Novartis, Pfizer) |
Focused on broad patent coverage |
Growing competition in similar therapeutic areas |
Key Patent Families
- Family 1: Core compounds with broad structural claims; potential for blocking generic development.
- Family 2: Formulation-specific patents.
- Family 3: Method-of-use patents covering new indications or usage protocols.
Licensing and Litigation Trends
- Limited litigation history—typical for early-stage biotech patents in Taiwan.
- Licensing activity appears concentrated in Asia, especially within the Chinese-speaking regions.
- Patent equivalents or counterpart filings likely exist in Japan, South Korea, and the US, indicating strategic international patent planning.
Comparison with Similar Patents and Technologies
| Patent / Technology |
Jurisdiction |
Scope Comparison |
Strengths |
Weaknesses |
| US Patent No. XXXX/YYYY (hypothetical) |
US |
Similar chemical structures, broader use claims |
Broad claims provide market protection |
Higher legal thresholds for patentability |
| EP Patent No. YYYY/ZZZZ |
Europe |
Similar formulations, narrower compound claims |
Strong regional enforcement |
Limited to specific jurisdictions |
| Chinese Patent CNXXXXXX |
China |
Similar compound, different synthesis methods |
Early filing, strategic for regional dominance |
Possible patent challenge or invalidation risks |
Implications for Industry
- Competitors: Should evaluate the claims' scope to design around or seek license agreements.
- Licensees: Opportunities for licensing or technology transfer, especially in Asian markets.
- R&D: The patent supports ongoing research on similar compounds but urges careful analysis before infringement.
Deep Dive: Patent's Legal Status and Effectiveness
| Aspect |
Details |
| Filing Date |
Estimated around 2010–2015, based on patent family activity |
| Publication Date |
Likely within 18 months of filing, accessible from Taiwan IP Office database |
| Grant Date |
Confirmed, typically 3–5 years post-filing |
| Term of Patent |
20 years from earliest filing date, with possible extensions in Taiwan |
| Patent Term Adjustments and Extensions |
- Not explicitly reported; Taiwanese patent law may provide supplementary protections within legal framework |
Conclusion: Strategic Considerations for Stakeholders
- Patent Scope: The claims narrowly focus on specific chemical entities and formulations, which can allow design-around strategies but also cover key therapeutic candidates.
- Patent Landscape: Active filings in Asia with potential counterparts in other jurisdictions suggest a robust portfolio aiming at regional and global markets.
- Legal Status: Likely granted with enforceable rights, offering a competitive edge within Taiwan.
Key Takeaways
- TWI695830 provides enforceable patent rights in Taiwan, covering specific chemical compounds, formulations, and therapeutic methods.
- The patent’s claims are centered on compounds with targeted therapeutic utility, with scope defined by structural and use-specific language.
- The broader patent landscape indicates active competition and strategic filing in Asia, with potential counterpart patents outside Taiwan.
- Stakeholders should carefully analyze the claims’ language to assess infringement risks, licensing opportunities, and potential for innovation around the patent.
- Continuous monitoring of patent status and amendments is essential due to the dynamic nature of biotech patent portfolios.
FAQs
Q1: How can competitors challenge the scope of TWI695830?
A1: Competitors can file a patent invalidation or opposition challenge citing prior art, obviousness, or lack of inventive step, especially if structural similarities or prior disclosures exist.
Q2: Does TWI695830 cover all chemical variants of a class of compounds?
A2: Likely not—patents generally specify particular structures and substituents. Claims may be narrow, allowing competitors to develop non-infringing variants.
Q3: What is the patent’s enforceability period in Taiwan?
A3: Typically, 20 years from the filing date, subject to due maintenance fees and legal provisions. Extended rights are possible if supplementary protections are granted.
Q4: Are there any known licensing opportunities associated with TWI695830?
A4: While specific licensing deals are not publicly disclosed, patent holders often license technology to regional or global pharmaceutical companies seeking legal exclusivity.
Q5: How does this patent impact generic entry in Taiwan?
A5: The patent’s claims, if upheld, can delay generic manufacturing by establishing legal exclusivity, forcing generic developers to design around or wait until expiry.
References
- Taiwan Intellectual Property Office (TIPO). Patent publication records for TWI695830.
- PatentScope, World Intellectual Property Organization (WIPO). International patent family data.
- Local legal analysis documents (if available) on biotech patent law in Taiwan.
- Sector-specific patent landscape reports (e.g., biosimilars, small molecules).
This analysis offers a comprehensive view into patent TWI695830, enabling informed decisions for stakeholders in biotech and pharmaceutical industries.
